This article was originally published in SRA
European Commission publishes second report
You may also be interested in...
Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.